Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial

• Main Authors: Enzo Errichetti (Author), Peter Wolf (Author), Saakshi Khattri (Author), Patricia Gorecki (Author), Megan Miller (Author), Jingzhi Jiang (Author), Chenglong Han (Author), Brian Kirby (Author)
• Format: Book
• Published: Medical Journals Sweden, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Mild psoriasis may be burdensome; if symptoms are inadequately controlled, switching therapy may be warranted. In the Phase 3 NAVIGATE trial, patients with moderate-to-severe plaque psoriasis received ustekinumab for 16 weeks. Patients with inadequate response (Investigator's Global Assessment...